XLO Xilio Therapeutics, Inc.
$8.01▲ +3.89%
Healthcare
Other
Volume 27.9K
Avg Volume (10D) 19.7K
Key Metrics & Fundamentals
Market Cap
$52.71M
P/E Ratio
–
Div Yield
0.00%
52W Range
6.47 - 12.59
% vs 50 MA
-9.88%
% vs 200 MA
-5.91%
RSI-14
39.7
MACD Histogram
-0.1300
Beta (1Y vs SPY)
0.90
Free Cash Flow
-$18.78M
Gross Rev
$18.69M
Gross Profit
$18.69M
EBITDA
$780,000
COGS
–
Operating Exp
$22.18M
Operating Income
-$3.49M
EBIT
-$3.49M
Pretax Income
-$6.37M
Net Income
-$6.37M
EPS (Diluted)
-0.33
Price & Volume History
Loading chart…
Recent News
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
GlobeNewswire · Oct 26, 2026 7:30 AM ET
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 4:30 PM ET
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
GlobeNewswire · Sep 28, 2026 7:30 AM ET
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 2, 2026 4:30 PM ET
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
GlobeNewswire · Aug 12, 2026 7:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See XLO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.